Posted by Michael Wonder on 02 Jul 2020
Acacia Pharma announces US FDA approval of Byfavo (remimazolam) for injection for the induction and maintenance of procedural sedation
2 July 2020 - Byfavo is a very rapid onset/offset IV benzodiazepine sedative for use during invasive medical procedures lasting 30 minutes or less, such as colonoscopy and bronchoscopy.
Acacia Pharma announces that the US FDA has approved Byfavo (remimazolam) for injection for the induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less.
Acacia Pharma in-licensed the commercial rights to Byfavo for the US from Cosmo Pharmaceuticals in January 2020. Remimazolam was developed by Paion.
